#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Glomerulonephritis chronic Muscular dystrophy Canavan disease Cushing's syndrome Short stature homeobox gene mutation Nephropathy Oesophageal squamous cell carcinoma stage II Infantile spasms Systemic sclerosis pulmonary Isodicentric chromosome 15 syndrome Non-small cell lung cancer Deafness neurosensory Ocular lymphoma Oesophageal adenocarcinoma stage II Prolymphocytic leukaemia More trials…

    Learn about Rare Diseases

    Cerebral arteriovenous malformation haemorrhagic – Treatment Hairy cell leukaemia recurrent Waldenstrom’s macroglobulinaemia refractory – Life with Disease Toxic epidermal necrolysis Alport’s syndrome Waldenstrom’s macroglobulinaemia Mantle cell lymphoma stage III – Basic Information Hereditary ataxia – Basic Information Familial amyotrophic lateral sclerosis – Trials in Disease Glomerulonephritis membranoproliferative – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Vixarelimab Gns561 Pristinamycin RUBIDIUM CHLORIDE Lysine Hydrochloride Cldn6 Car-T(A) Esomeprazole RP2 L-PHENYLALANINE TEV-53408 Sulfamethizole Nilutamide Glatiramer Acetate Silibinin Dc-806 Mosaic Hbcoreag Platelet Concentrate Dorocubicel Sar441566 Fluticasone Propionate More therapies…

    Learn about Your Condition

    Loeys-Dietz syndrome Scoliosis Ewing's sarcoma recurrent Malignant lymphoid neoplasm Diabetic nephropathy Incisional hernia Ovarian cancer Vascular calcification Endometriosis Metabolic surgery Hypotension Diarrhoea Familial hypertriglyceridaemia Gastrectomy Seizure More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

IgA nephropathy

  • Study on the Effect of Hydroxychloroquine for Patients with IgA Nephropathy and High Albumin Levels

    Recruiting

    3 1 1
    Investigated Diseases:
    • IgA nephropathy
    Investigated Drugs:
    • Hydroxychloroquine Sulfate
    France

  • Long-Term Safety Study of Iptacopan for Adults with IgA Nephropathy After Completing a Previous Study, Including ACE Inhibitors and ARBs Drug Combination

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • IgA nephropathy
    Investigated Drugs:
    • Ace Inhibitors, Plain
    • Angiotensin Ii Receptor Blockers (Arbs), Combinations
    • Angiotensin Ii Receptor Blockers (Arbs), Plain
    Belgium Czechia Denmark France Germany Hungary +7

  • Study on the Safety and Effects of Sparsentan for Children with Proteinuric Kidney Diseases

    Recruiting

    2 1 1
    Investigated Diseases:
    • Glomerulonephritis minimal lesion
    • Focal segmental glomerulosclerosis
    • Alport’s syndrome
    Investigated Drugs:
    • Sparsentan
    Germany Italy The Netherlands Poland Spain Sweden

  • Study on the Long-term Safety and Effectiveness of Sibeprenlimab for Patients with Immunoglobulin A Nephropathy (IgAN)

    Recruiting

    4 1 1
    Investigated Drugs:
    • Sibeprenlimab
    Belgium Croatia Czechia France Germany Greece +6

  • Long-Term Safety Study of Zigakibart in Adults with IgA Nephropathy Who Have Completed Previous Zigakibart Trials

    Recruiting

    3 1 1
    Investigated Drugs:
    • ZIGAKIBART
    Belgium Croatia Czechia France Germany Greece +2

  • Study of atrasentan in children aged 2 to <18 years with primary IgA nephropathy to evaluate proteinuria reduction, safety and tolerability

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • IgA nephropathy
    Investigated Drugs:
    • Atrasentan Hydrochloride
    France Spain
Previous Page
1 2 3 4
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!